LITTLE ROCK, Ark. (AP) - A judge will decide how much a Johnson & Johnson and a subsidiary must pay the state of Arkansas, after a jury found the company downplayed and hid risks associated with an antipsychotics drug.
Jurors returned a quick verdict Tuesday in favor of the state. Arkansas attorneys argued that Janssen Pharmaceuticals Inc. lied about potentially life-threatening side effects of Risperdal.
A hearing on how much Johnson & Johnson and its subsidiary must pay is scheduled for Wednesday morning.
The state is asking for at least $1.2 billion. That amounts to $480 for each of the 250,000 Risperdal prescriptions the state's Medicaid program paid for over 3½ years.
Previous verdicts against J&J include a $327 million civil penalty in South Carolina.
Texas reached a $158 million settlement with Janssen in January.